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The identification of membrane-active regions of the ectodomain of the HIV-1 envelope glycoprotein gp41 has been made by
determining the effect on membrane integrity of a 15-mer gp41-derived peptide library. By monitoring the effect of this peptide library
on membrane leakage, we have identified three regions on the gp41 ectodomain with membrane-interacting capabilities: Region 1,
which would roughly correspond to the polar sequence which follows the fusion domain and extends to the N-terminal heptad repeat
region; Region 2, which would correspond to the immunodominant loop; and Region 3, which would correspond to the pre-
transmembrane region of gp41. The identification of these three regions supports their direct role in membrane fusion as well as
facilitating the future development of HIV-1 entry inhibitors.
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The attachment of enveloped viruses to cells and the
consequent fusion of viral and cellular membranes, the
critical early events in viral infection are mediated by
envelope glycoproteins (gp) located on the outer surface
of the viral membrane [1,2]. The human immunodeficien-
cy virus type 1 (HIV-1) envelope glycoprotein, gp160,
synthesized as a precursor, is proteolytically cleaved into
the receptor binding subunit, gp120, and the fusogenic
subunit, gp41, which remain non-covalently associated
with one another. The native conformation of gp41 is
metastable and is stabilized by gp120. Binding of gp1200005-2736/$ - see front matter D 2004 Elsevier B.V. All rigths reserved.
doi:10.1016/j.bbamem.2003.12.003
Abbreviations: CF, 5-carboxyfluorescein; Chol, cholesterol; CHR, C-
terminal heptad repeat region; gp, glycoprotein; HIV-1, human immuno-
deficiency virus type 1; LUV, large unilamellar vesicles; NHR, N-terminal
heptad repeat region; PA, egg L-a-phosphatidic acid; PC, egg L-a-
phosphatidylcholine; PE, egg L-a-phosphatidylethanolamine; PI, bovine
liver L-a-phosphatidylinositol; POPC, palmitoyloleoylphosphatidylcholine;
PS, bovine brain phosphatidylserine; PSM, palmitoylsphingomyelin; SM,
egg sphingomyelin; Tm, main transition temperature
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E-mail address: jvillalain@umh.es (J. Villalaı´n).to the cell-surface receptors and co-receptors, triggers a
series of conformational changes in gp41, resulting in
exposure of the fusion peptide and its insertion into the
host membrane, followed by juxtaposition of viral and
host cell membranes, and finally leading to activation of
its membrane fusion properties [1–5]. At the N terminus
of gp41, a stretch of about 15 hydrophobic residues (see
Fig. 1A), named the fusion peptide [6,7] is believed to
insert into and destabilize the membrane, thus facilitating
viral and cell membrane fusion [8]. Consecutive to the
fusion peptide and preceding the transmembrane domain,
two heptad repeat regions (NHR and CHR, respectively)
have been identified [9]. In the absence of lipid mem-
branes, three NHR molecules fold into a central parallel
triple-stranded a-helical coiled-coil, and wrapped anti-
parallel on the outside of this core is an outer layer of
three anti-parallel CHR a-helices, each pair of NHR/CHR
molecules connected by the immunogenic, protease-sensi-
tive loop that reverses the polypeptide chain [4,5,10]. This
trimeric helical hairpin structure is thought to form at a
late stage during the membrane fusion process [4,5].
It has been proposed that the existence of a ‘‘pre-
hairpin intermediate’’ in gp41-induced membrane fusion
in which the N-terminal coiled-coil is formed, but the C-
terminal helices are not packed [11]. At this stage, the C-
Fig. 1. (A) Scheme of the structure of gp41, the fusogenic glycoprotein subunit of HIV-1, according to literature consensus. The sequence numbering follows
isolate HIV-1MN and the important functional regions are highlighted, i.e., the fusion domain, FD, the N- and C-heptad repeats, the immunodominant loop and
the transmembrane region, TM. (B) Sequence of the 15-mer peptides used in this study with respect to the sequence of gp41. Maximum overlap between
adjacent peptides is 11 amino acids. (C) Charge profile at pH 7.4 of the 15-mer peptides.
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thus preventing the subsequent refolding and blocking
fusion [12]. The pre-hairpin intermediate spans both
membranes, with the gp41 transmembrane domain an-
chored in the viral membrane, and the fusion peptide
inserted into the target cell membrane. Inhibition by N-
and C-peptides is thought to act at this level, by prevent-
ing transition to the hairpin/fusion structure [13,14]. The
transition from the pre-hairpin to the hairpin structure
brings the two membranes into close proximity, driving
fusion. Although much information has been gathered in
recent years, we do not yet know the exact mechanism of
membrane fusion and the processes which are behind
them.
Although it was initially believed that gp41 interacted
with the membrane solely by means of the N-terminal
fusion peptide and the transmembrane domain, it has
been shown that gp41 constructs lacking these two
segments bind and interact with the surface of phospho-
lipid bilayers as well as other regions of the ectodomain,
not only derived from gp41, but also from other viral
fusion proteins [15–20]. These and others observations
suggested the hypothesis that, upon interacting with the
membrane, HIV-1 gp41 undergoes an additional confor-
mational change in which the trimeric helical hairpin
binds to the membrane surface and opens [15]. Themechanism by which proteins facilitate the formation
of fusion intermediates is a complex process involving
several segments of fusion proteins [21,22]. These
regions, either directly or indirectly, might interact with
biological membranes, contributing to the viral envelope
and cell membrane merging. Although the detailed
structure of different segments of the gp41 ectodomain
of HIV-1 have been known for several years, there are
still many questions to be answered regarding its mode
of action in accelerating membrane fusion. Moreover,
HIV-1 entry is an attractive target for anti-HIV-1 therapy.
Therefore, we have initiated the first steps towards the
finding of inhibitors of gp41 membrane fusion by
identifying the regions of gp41 which might interact
with phospholipid membranes. The first one has been
the identification of membrane-active regions by deter-
mining the effect on membrane integrity of a 15-mer
gp41-derived peptide library. By monitoring the effect of
this peptide library on membrane integrity, i.e., leakage,
we have identified three different regions of gp41 with
membrane-interacting capabilities, supporting their direct
role in membrane fusion, and therefore might help in the
understanding of the molecular mechanism of membrane
merging as well as making possible the future develop-
ment of HIV-1 entry inhibitors which may lead to new
vaccine strategies.
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2.1. Materials and reagents
Egg L-a-phosphatidylcholine (PC), egg sphingomyelin
(SM), cholesterol (Chol), bovine brain phosphatidylserine
(PS), egg L-a-phosphatidylethanolamine (PE), egg L-a-
phosphatidic acid (PA) and bovine liver L-a-phosphatidyli-
nositol (PI) were obtained from Avanti Polar Lipids (Ala-
baster, AL, USA). 5-Carboxyfluorescein (CF), >95% by
HPLC, was from Sigma-Aldrich (Madrid, Spain). A set of
35 peptides of 15 amino acids in length derived from HIV-
1MN gp41, most of which with 11 amino acid overlaps
between sequential peptides, were obtained through the
AIDS Research and Reference Reagent Program (Division
of AIDS, NIAID, NIH, Bethesda, MD, USA). Peripheral
blood lymphocytes were obtained from healthy volunteers
using standard procedures (Hospital Universitario de Elche,
Alicante, Spain). Lipid extraction from human lymphocytes
was performed according to the Bligh and Dyer procedure
using a ratio of 1:1:0.9 (v/v/v) between chloroform/metha-
nol and the corresponding aqueous sample [23]. All other
reagents used were of analytical grade from Merck (Darm-
stadt, Germany). Water was deionized, twice-distilled and
passed through a Milli-Q equipment (Millipore Ibe´rica,
Madrid, Spain) to a resistivity better than 18 MV cm.
2.2. Sample preparation
Aliquots containing the appropriate amount of lipid in
chloroform/methanol (1:1, v/v) were placed in a test tube,
the solvents removed by evaporation under a stream of O2-
free nitrogen and finally, traces of solvents were eliminated
under vacuum in the dark for more than 3 h. After that, 2 ml
of buffer containing 20 mM Hepes, 50 mM NaCl, 0.1 mM
EDTA, pH 7.4 buffer was added, and multilamellar vesicles
were obtained. Large unilamellar vesicles (LUV) with a
mean diameter of 90 nm were prepared from multilamellar
vesicles by the extrusion method [24] using polycarbonate
filters with a pore size of 0.1 Am (Nuclepore Corp., Cam-
bridge, CA, USA) using 10 mM HEPES, 100 mM NaCl, 0.1
mM EDTA, pH 7.4 buffer and CF at a concentration of 40
mM. Breakdown of the vesicle membrane leads to contents
leakage, i.e., CF fluorescence. Non-encapsulated CF was
separated from the vesicle suspension through a Sephadex
G-75 filtration column (Pharmacia, Uppsala, Sweden) elut-
ed with buffer containing 10 mM HEPES, 150 mM NaCl,
0.1 mM EDTA, pH 7.4 [20].
2.3. Leakage measurement
Leakage of intraliposomal CF was assayed by treating
the probe-loaded liposomes (final lipid concentration, 0.5
mM) with the appropriate amount of peptide on microtiter
plates stabilized at 25 jC using a microplate reader (FLUOs-
tar, BMG Labtech, Germany), each well containing a finalvolume of 170 Al. The medium in the microtiter plates was
continuously stirred to allow the rapid mixing of peptide and
vesicles. Leakage was measured at an approximate peptide-
to-lipid ratio of 1:25. Changes in fluorescence intensity were
recorded with excitation and emission wavelengths set at
492 and 517 nm, respectively. One hundred percent release
was achieved by adding Triton X-100 to a final concentra-
tion of 0.5% (w/w) to the microtiter plates. Fluorescence
measurements were made initially with probe-loaded lip-
osomes, afterwards by adding peptide solution and finally
adding Triton X-100 to obtain 100% leakage. Leakage was
quantified on a percentage basis according to the equation,
%Release ¼ ð Ff  F0
F100  F0Þ  100
Ff being the equilibrium value of fluorescence after peptide
addition, F0 the initial fluorescence of the vesicle suspen-
sion and F100 the fluorescence value after addition of Triton
X-100. The phospholipid concentration was measured by
methods described previously [25].3. Results and discussion
Although it was previously thought that the N-terminal
fusion peptide of gp41 was the only responsible for cell
membrane interaction leading to membrane fusion, it has
been shown that other gp41 regions bind, interact and
undergo conformational changes in the presence of mem-
branes [21,22]. To explore the specific interaction of the 15-
mer gp41-ectodomain derived peptide library with phos-
pholipid model membranes, we have studied their effect on
the release of an encapsulated fluorophore, 5-carboxyfluor-
escein using the experimental set up described in Materials
and methods. The 35 peptides we have used in this study,
derived from the gp41 ectodomain, are shown in Fig. 1B
with respect to the gp41 sequence, whereas Fig. 1C shows
its charge at pH 7.4. As it can be observed in Fig. 1B, the
peptide scan extends from the sequence which follows the
fusion domain to the sequence which precedes the trans-
membrane domain, which also includes a small amino acid
stretch of both hydrophobic domains. The peptide scan
library encompasses also the NHR, CHR and loop regions
(Fig. 1A and B).
Fig. 2 shows the effect of the peptide scan on membrane
integrity, i.e., leakage, for four different liposome composi-
tions, namely EPC, EPC/Chol at a molar ratio of 5:1, EPC/
BPS/Chol at a molar ratio of 4:4:1 and EPC/EPE/Chol at a
molar ratio of 5:3:1. For liposomes composed of EPC (Fig.
2A), it is clearly evident that some peptides hardly exerted
any effect on EPC liposomes, but other ones showed a
significant effect. The most notable effect was observed for
peptide no. 15, which produced a leakage of about 90%, i.e.,
a near complete rupture of the liposomes. Other peptides
induced less leakage though a significant one, such as
Fig. 2. Effect of the gp41-derived 15-mer peptides on the release of LUV contents for different lipid compositions. Leakage data for LUV composed of (A)
EPC, (B) EPC/Chol at a molar ratio of 5:1, (C) EPC/BPS/Chol at a molar ratio of 4:4:1 and (D) EPC/EPE/Chol at a molar ratio of 5:3:1. Vertical bars indicate
standard deviations of the mean of triplicate samples.
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leakage. Other peptides showed leakage values between
10% and 20% (peptides no. 2, 6, 8, and 32). Similarly to
what was found using EPC liposomes, some peptides
interacted significantly with liposomes composed of EPC/
Chol at a molar ratio of 5:1 (see Fig. 2B), although there
were several ones that have hardly any effect. As above, the
most significant effect was observed for peptide no. 15,
which showed leakage values of about 75%. The leakage
extent for this type of liposomes was in general slightly
lower than that found on EPC liposomes; interestingly, the
same peptides that showed a significant effect on EPC
liposomes were the ones that showed a significant one for
EPC/Chol liposomes. Peptides no. 3 and 6 were the ones
which presented a greater extent of leakage but also peptides
no. 2 and 8 presented significant leakage values (see Fig.
2B). It should be noted that inclusion of Chol in membranesreduced peptide-induced membrane leakage as it has been
shown before [26]; however, the presence of Chol seems to
be a specific requirement for HIV-1 infection (Ref. [27]; see
below). The extent of leakage observed in liposomes com-
posed of EPC/BPS/Chol at a molar ratio of 4:4:1 (Fig. 2C),
was much lower than that found for both EPC and EPC/
Chol liposomes. Except for peptide no. 3, which presented
leakage values slightly above 20%, the other peptides
presented small leakage values or no leakage at all (i.e.,
peptide no. 15, which in either EPC or EPC/Chol liposomes
showed significant leakage values). It is worth to note that
the major difference between EPC/BPS/Chol liposomes and
EPC or EPC/Chol liposomes is the negative net charge the
former has (compare the net charge of the different peptides
at pH 7.4 shown in Fig. 1C). Liposomes composed of EPC/
EPE/Chol at a molar ratio of 5:3:1 showed slightly lower
leakage values than those found for EPC or EPC/Chol
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liposomes (Fig. 2D). For this liposome composition, peptide
no. 15 produced leakage values of about 40%, whereas
peptides no. 2, 3 and 6 showed leakage values between 10%
and 30%. It is worth to note that peptides no. 32–34 showed
a limited extent of leakage for EPC liposomes but hardly
detected values for the other liposomes (Fig. 2), the major
difference being Chol content (see below). By observing the
leakage values driven by the 15-mer peptide library on these
different liposome compositions, two delimited regions
could be discerned, one which would roughly correspond
to the polar sequence which follows the fusion domain and
extends to the NHR region (Region 1, comprising peptides
2, 3, 6 and 8, Fig. 5) and another one which would
correspond to the immunodominant loop (Region 2, com-
prising peptides 15 and 16, Fig. 5).
It was previously thought that the lipid composition of
the HIV-1 envelope was similar to that of cell plasma
membranes; however, its phospholipid profile and fluidity
is notably different from plasma membranes of the host
cells, the most significant difference being is higher
content of Chol and SM [28]. Both lipids, which have
a propensity to form an ordered domain separate from the
more liquid plasma membrane, rich in other lipids, have
been related to the occurrence of laterally segregated
membrane microdomains or ‘‘lipid rafts’’ [29–31]. Earlier
studies have demonstrated an important relationship be-
tween membrane fusion and Chol and SM membrane
content for several enveloped viruses. For example, Sem-
liki Forest virus requires Chol for membrane fusion
[32,33] and the presence of SM enhances the mem-
brane-destabilizing capacity of the pre-transmembrane
sequence of Ebola glycoprotein [34]. HIV-1 uses Chol
and sphingolipids during budding [35], and several
domains within the gp41 C-helix either interact with Chol
or with sphingolipids or both [36–38]. Interestingly, CD4
receptors are presumably located in lipid rafts [39] and
relocation of CD4/viral proteins outside rafts might be
important steps in the fusion process [40]. All these data
strongly suggest that the interaction of gp41 with Chol
and SM might play a major role in the fusion process [2].
Because of that, we have studied the interaction of the
15-mer gp41-ectodomain peptide library with model
membranes having a variable Chol and SM composition,
namely, EPC/SM at a molar ratio of 5:1 and EPC/SM/
Chol at molar ratios of 17:2:1, 5:1:1, 26:9:15 and
37:18:45 (Fig. 3). Recently, a ternary phase diagram for
palmitoylsphingomyelin (PSM), palmitoyloleoylphosphati-
dylcholine (POPC) and Chol, a typical raft-containing
lipid mixture, has been determined [41]. If the ternary
phase diagram for POPC/SM/Chol were applicable to
EPC, SM, and Chol, the lipids used in this study,
liposomes containing EPC/Chol at a molar ratio of 5:1
and liposomes containing EPC/SM/Chol at a molar ratio
of 17:2:1 would be predominantly in the liquid-disordered
phase, whereas liposomes containing EPC/SM/Chol atmolar ratios of 5:1:1, 26:9:15 and 37:18:45 would present
a coexistence of liquid-ordered and liquid-disordered
phases, i.e., a high probability of raft formation [42,43].
For liposomes composed of EPC/SM at a molar ratio
of 5:1 (Fig. 3A), it is clearly evident the significant effect
on leakage produced by some peptides, whereas any
effect was observed for other ones. Interestingly, peptides
no. 15 and 16, which showed a significant effect on EPC-
containing LUVs (peptide no. 15 significantly more than
peptide no. 16, see Fig. 2) also produced a significant
effect on these EPC/SM LUVs, since a complete rupture
of the liposomes was observed (ca. 100% leakage for
peptide no. 15, about 60% for peptide no. 16). Other
peptides, such as no. 3, 8 and 9, produced a significant
leakage, i.e., between 20% and 40%, similarly to what
was found before (see Fig. 2). Other peptides, which did
not produce any significant leakage in the other liposome
compositions described above, now produced a significant
one, i.e., peptides no. 32 and 33, which showed leakage
values ranging from 20% to 40%. It is interesting to note
that peptides no. 32 and 33 correspond to the pre-
transmembrane sequence of gp41, region which has been
implicated in the specific interaction of gp41 with Chol
and SM containing membranes [37]. Liposomes com-
posed of EPC/SM/CHOL at a molar ratio of 17:2:1
showed slightly lower leakage values than those found
using liposomes containing EPC/SM at a molar ratio of
5:1 but the pattern was essentially the same (Fig. 3B).
Liposomes composed of EPC/SM/CHOL at molar ratios
of 5:1:1, 26:9:15 and 37:18:45 showed similar results. For
example, peptides no. 15 and 16 presented the higher
effect on leakage, peptides no. 3, 8 and 9 smaller but
significant leakage values, similarly to peptides no. 32
and 33, whose leakage values ranged from about 15% to
about 40%. This pattern is essentially the same for all
liposomes containing Chol and SM. Therefore, and in
contrast to what was shown above, three, instead of two,
delimited regions are apparent in the leakage diagrams
shown in Fig. 3: two regions identical to the ones which
were described above (Regions 1 and 2, Fig. 5) and a
new one, which would correspond to the pre-transmem-
brane region of gp41 (Region 3, comprising peptides no.
32, 33 and 34, Fig. 5).
As we have noted above, lipid composition of plasma
cell membranes differ significantly from HIV-1 envelopes
[28] and we have found different effects on leakage when
including SM in liposome composition. Taking into
account this fact, we have also studied the effect of the
15-mer peptide library on liposomes whose composition
resemble the lipid composition of un-infected cell plasma
membranes [28], i.e., LUVs whose composition is PC/PE/
SM/PS/PI/PA/Chol at a molar ratio of 47:23:10:10:5:0.5:3
(Fig. 4A). Leakage values are similar to those found for
EPC-containing liposomes but dissimilar to those contain-
ing SM (compare with Figs. 2 and 3). The most effective
peptide in provoking leakage for these liposomes is again
Fig. 3. Effect of the gp41-derived 15-mer peptides on the release of LUV contents for different lipid compositions. Leakage data for LUV composed of (A)
EPC/SM at a molar ratio of 5:1, (B) EPC/SM/Chol at a molar ratio of 17:2:1, (C) EPC/SM/Chol at a molar ratio of 5:1:1, (D) EPC/SM/Chol at a molar ratio of
26:9:15 and (E) EPC/SM/Chol at a molar ratio of 37:18:45. Vertical bars indicate standard deviations of the mean of triplicate samples.
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peptides which show a significant effect are peptides no.
3 and 8, whose leakage values lie between 20% and 40%
(see Fig. 4). Interestingly, hardly any effect is observedfor peptides which correspond to the pre-transmembrane
region of gp41. It is interesting to note that these lip-
osomes, apart from containing Chol and SM, also include
PS, whose presence reduced leakage to a great extent (see
Fig. 5. Scheme of the HIV-1 gp41 structure, along with a summary of the
data obtained in this work. Regions 1, 2 and 3, as specified in the text, are
shown in dark grey.
Fig. 4. Effect of the gp41-derived 15-mer peptides on the release of LUV
contents for (A) PC/PE/SM/PS/PI/PA/Chol at a molar ratio of
47:23:10:10:5:0.5:3 and (B) lipidic extract of lymphocytes. Experimental
conditions are described in the text. Vertical bars indicate standard
deviations of the mean of triplicate samples.
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lipids were obtained from a lipidic extract of lymphocytes
(see Fig. 4B; note the increase in leakage scale). It can be
observed that the extent of leakage has been very much
reduced compared to the other LUV systems studied
above. However, similar patterns of leakage to those
described above can be discerned, delimiting in this case
two regions, the polar sequence which follows the fusion
domain and the immunodominant loop, as described
above (Regions 1 and 2, Fig. 5).Several lines of evidence indicate that, in addition to
classical fusion peptides, different regions of the gp41
ectodomain are essential for membrane fusion to occur.
For example, synthetic peptides that partially overlap the
CHR segment and a consecutive Trp-rich region have been
shown to be potent inhibitors of gp41-mediated membrane
fusion [3,11,44], deletion of short sequences within the
CHR region reduce fusogenicity, whereas longer deletions
abolish it completely [45,46], the CHR region is highly
conserved in the vast majority of otherwise highly variable
HIV-1 isolates [46], some peptides coming from both NHR
and CHR regions as well as from the immunodominant loop
show membrane binding, causing membrane leakage in
different experimental conditions [19,20,47] and the inhib-
itory effect of some peptides appears conditioned by their
ability to partition into membranes and aggregate within
them [48]. In concordance with these findings, our results
demonstrate that peptides originated from three different
gp41 regions (Fig. 5), namely Region 1, which corresponds
to the 15–20 residues peptide segment which follows the
fusion peptide at the N-terminus, Region 2, which corre-
sponds to the immunodominant loop, and Region 3, which
corresponds to the 10–15 residues peptide segment which
precedes the transmembrane domain at the C-terminus, are
capable of modifying the biophysical properties of phos-
pholipid membranes, a property which could provide an
additional driving force for the merging of the viral and
target cell membranes, supports their direct role in mem-
brane fusion and therefore might be essential for the
assistance and enhancement of the viral and cell fusion
process. Our results should also facilitate the development
of HIV-1 entry inhibitors, which might lead to new vaccine
strategies, an important focus for clinical intervention.
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